Logo image of FBIOP

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FBIOP - US34960Q2084

7.2095 USD
-0.67 (-8.51%)
Last: 12/11/2025, 12:53:01 PM
Fundamental Rating

2

FBIOP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of FBIOP have multiple concerns. FBIOP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FBIOP has reported negative net income.
FBIOP had a negative operating cash flow in the past year.
In the past 5 years FBIOP always reported negative net income.
In the past 5 years FBIOP always reported negative operating cash flow.
FBIOP Yearly Net Income VS EBIT VS OCF VS FCFFBIOP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With an excellent Return On Assets value of -2.94%, FBIOP belongs to the best of the industry, outperforming 86.63% of the companies in the same industry.
Looking at the Return On Equity, with a value of -9.55%, FBIOP belongs to the top of the industry, outperforming 87.76% of the companies in the same industry.
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIOP Yearly ROA, ROE, ROICFBIOP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

FBIOP has a better Gross Margin (71.56%) than 82.11% of its industry peers.
FBIOP's Gross Margin has declined in the last couple of years.
FBIOP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIOP Yearly Profit, Operating, Gross MarginsFBIOP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

FBIOP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FBIOP has more shares outstanding
FBIOP has more shares outstanding than it did 5 years ago.
FBIOP has a worse debt/assets ratio than last year.
FBIOP Yearly Shares OutstandingFBIOP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIOP Yearly Total Debt VS Total AssetsFBIOP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.39, we must say that FBIOP is in the distress zone and has some risk of bankruptcy.
FBIOP's Altman-Z score of -5.39 is on the low side compared to the rest of the industry. FBIOP is outperformed by 64.41% of its industry peers.
A Debt/Equity ratio of 0.86 indicates that FBIOP is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.86, FBIOP is doing worse than 75.14% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -5.39
ROIC/WACCN/A
WACC9.41%
FBIOP Yearly LT Debt VS Equity VS FCFFBIOP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

A Current Ratio of 2.19 indicates that FBIOP has no problem at all paying its short term obligations.
FBIOP has a Current ratio of 2.19. This is in the lower half of the industry: FBIOP underperforms 75.33% of its industry peers.
FBIOP has a Quick Ratio of 1.97. This is a normal value and indicates that FBIOP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.97, FBIOP is doing worse than 75.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.97
FBIOP Yearly Current Assets VS Current LiabilitesFBIOP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.37% over the past year.
Looking at the last year, FBIOP shows a decrease in Revenue. The Revenue has decreased by -0.32% in the last year.
The Revenue has been growing by 9.50% on average over the past years. This is quite good.
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%

3.2 Future

The Earnings Per Share is expected to grow by 11.48% on average over the next years. This is quite good.
The Revenue is expected to grow by 64.44% on average over the next years. This is a very strong growth
EPS Next Y80.35%
EPS Next 2Y22.89%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FBIOP Yearly Revenue VS EstimatesFBIOP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIOP Yearly EPS VS EstimatesFBIOP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBIOP. In the last year negative earnings were reported.
Also next year FBIOP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBIOP Price Earnings VS Forward Price EarningsFBIOP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIOP Per share dataFBIOP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.89%
EPS Next 3Y11.48%

More info and screens

0

5. Dividend

5.1 Amount

FBIOP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP

NASDAQ:FBIOP (12/11/2025, 12:53:01 PM)

7.2095

-0.67 (-8.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-24 2026-03-24/amc
Inst Owners15.05%
Inst Owner ChangeN/A
Ins Owners14.3%
Ins Owner ChangeN/A
Market Cap223.78M
Revenue(TTM)62.30M
Net Income(TTM)-5.34M
Analysts82.5
Price Target28.51 (295.45%)
Short Float %0%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-12.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.76%
Min EPS beat(2)-36.17%
Max EPS beat(2)125.68%
EPS beat(4)3
Avg EPS beat(4)24.21%
Min EPS beat(4)-36.17%
Max EPS beat(4)125.68%
EPS beat(8)6
Avg EPS beat(8)23.87%
EPS beat(12)7
Avg EPS beat(12)18.85%
EPS beat(16)9
Avg EPS beat(16)-3.2%
Revenue beat(2)1
Avg Revenue beat(2)-3.53%
Min Revenue beat(2)-17.76%
Max Revenue beat(2)10.71%
Revenue beat(4)2
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-17.76%
Max Revenue beat(4)10.85%
Revenue beat(8)3
Avg Revenue beat(8)-5.02%
Revenue beat(12)5
Avg Revenue beat(12)3.82%
Revenue beat(16)6
Avg Revenue beat(16)-2.87%
PT rev (1m)-2.51%
PT rev (3m)-50.77%
EPS NQ rev (1m)21.59%
EPS NQ rev (3m)-6.7%
EPS NY rev (1m)36.36%
EPS NY rev (3m)55%
Revenue NQ rev (1m)-3.54%
Revenue NQ rev (3m)-32.99%
Revenue NY rev (1m)-1.63%
Revenue NY rev (3m)-14.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.59
P/FCF N/A
P/OCF N/A
P/B 4.01
P/tB 8.23
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS2.01
BVpS1.8
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.56%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.97
Altman-Z -5.39
F-Score4
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
EPS Next Y80.35%
EPS Next 2Y22.89%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.89%
EBIT Next 3Y5.48%
EBIT Next 5YN/A
FCF growth 1Y42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.14%
OCF growth 3YN/A
OCF growth 5YN/A

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ

Can you provide the ChartMill fundamental rating for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?

ChartMill assigns a fundamental rating of 2 / 10 to FBIOP.


What is the valuation status of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) stock?

ChartMill assigns a valuation rating of 0 / 10 to FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP). This can be considered as Overvalued.


What is the profitability of FBIOP stock?

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a profitability rating of 2 / 10.


What is the expected EPS growth for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) stock?

The Earnings per Share (EPS) of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is expected to grow by 80.35% in the next year.